Lycitra-MK Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby alleviating symptoms like sneezing, nasal congestion, rhinorrhea, and itching. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, which are inflammatory mediators involved in bronchoconstriction and increased mucus production, contributing to asthma and allergic rhinitis pathophysiology. The synergistic effect of these agents provides comprehensive relief from nasal and respiratory allergy symptoms by targeting multiple inflammatory pathways. Lycitra-MK is typically administered once daily, preferably in the evening, to enhance patient compliance and therapeutic efficacy. It is well-tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. This combination therapy should be used under medical supervision, especially in pediatric and elderly populations. Overall, Lycitra-MK Tablet offers an effective and convenient option for patients requiring dual-action treatment for allergic respiratory disorders.